Case Study

Ulcerative Colitis Study Gets Back On Track With Recruitment Support In Four Countries

Source: Trialbee AB
iStock-1232630835-patient-doctor

A global biotech initiated a phase IIb orphan drug study for the treatment of chronic ulcerative colitis.

Study protocol originally accounted for randomizing 120 patients across 40 investigator sites in six EU countries. Full enrollment was expected after 14 months of campaigning.

However, after deploying traditional recruitment methods, the sponsor met only 60% of its patient enrollment target, and extended the recruitment window an additional six months.

This case study reviews how Trialbee partnered with the biotech to close the enrollment gap and move the study forward as planned.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: